We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?
Read MoreHide Full Article
Have you been paying attention to shares of NeoGenomics (NEO - Free Report) ? Shares have been on the move with the stock up 4.5% over the past month. The stock hit a new 52-week high of $16.35 in the previous session. NeoGenomics has gained 34.7% since the start of the year compared to the -0.4% move for the Zacks Medical sector and the 0.8% return for the Zacks Medical - Biomedical and Genetics industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on July 28, 2026, NeoGenomics reported EPS of $0.05 versus consensus estimate of $0.03.
For the current fiscal year, NeoGenomics is expected to post earnings of $0.17 per share on $802.67 in revenues. This represents a 50% change in EPS on a 10.36% change in revenues. For the next fiscal year, the company is expected to earn $0.35 per share on $882.33 in revenues. This represents a year-over-year change of 95.83% and 9.93%, respectively.
Valuation Metrics
NeoGenomics may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
NeoGenomics has a Value Score of C. The stock's Growth and Momentum Scores are A and A, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 90.5X current fiscal year EPS estimates, which is a premium to the peer industry average of 21.3X. On a trailing cash flow basis, the stock currently trades at 47.3X versus its peer group's average of 13X. Additionally, the stock has a PEG ratio of 1.79. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to consider the stock's Zacks Rank, as this is even more important than the company's VGM Score. Fortunately, NeoGenomics currently has a Zacks Rank of #2 (Buy) thanks to a solid earnings estimate revision trend.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if NeoGenomics meets the list of requirements. Thus, it seems as though NeoGenomics shares could still be poised for more gains ahead.
View the Zacks #1 Rank List
Image: Bigstock
NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?
Have you been paying attention to shares of NeoGenomics (NEO - Free Report) ? Shares have been on the move with the stock up 4.5% over the past month. The stock hit a new 52-week high of $16.35 in the previous session. NeoGenomics has gained 34.7% since the start of the year compared to the -0.4% move for the Zacks Medical sector and the 0.8% return for the Zacks Medical - Biomedical and Genetics industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on July 28, 2026, NeoGenomics reported EPS of $0.05 versus consensus estimate of $0.03.
For the current fiscal year, NeoGenomics is expected to post earnings of $0.17 per share on $802.67 in revenues. This represents a 50% change in EPS on a 10.36% change in revenues. For the next fiscal year, the company is expected to earn $0.35 per share on $882.33 in revenues. This represents a year-over-year change of 95.83% and 9.93%, respectively.
Valuation Metrics
NeoGenomics may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
NeoGenomics has a Value Score of C. The stock's Growth and Momentum Scores are A and A, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 90.5X current fiscal year EPS estimates, which is a premium to the peer industry average of 21.3X. On a trailing cash flow basis, the stock currently trades at 47.3X versus its peer group's average of 13X. Additionally, the stock has a PEG ratio of 1.79. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to consider the stock's Zacks Rank, as this is even more important than the company's VGM Score. Fortunately, NeoGenomics currently has a Zacks Rank of #2 (Buy) thanks to a solid earnings estimate revision trend.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if NeoGenomics meets the list of requirements. Thus, it seems as though NeoGenomics shares could still be poised for more gains ahead.